Literature DB >> 17446262

CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.

Charles W Locuson1, Larry C Wienkers, Jeffrey P Jones, Timothy S Tracy.   

Abstract

The hemoprotein cytochrome b(5) (cyt b5) has been demonstrated to affect the kinetics of drug oxidation by the microsomal cytochromes P450 (P450s). However, the mechanisms through which cyt b5 exerts these effects are variable and P450 isoform-dependent. Whereas the effects of cyt b5 on the major drug-metabolizing enzymes CYP2D6, CYP2E1, and CYP3A4 are well studied, fewer studies conducted over limited ranges of cyt b5 concentrations have been performed on CYP2C9. In the present study with CYP2C9, cyt b5 exerted complex actions upon P450 oxidative reactions by affecting the rate of metabolite formation, the consumption of NADPH by cytochrome P450 reductase, and uncoupling of the reaction cycle to hydrogen peroxide and water. Cytochrome b(5) devoid of the heme moiety (apo-b5) exhibited effects similar to those of native cyt b5. All rates were highly dependent on the cyt b5 to CYP2C9 enzyme ratio, suggesting that the amount of cyt b5 present in an in vitro incubation is an important factor that can have an impact on the reliability of extrapolating in vitro generated data to predict the in vivo condition. The major effects of cyt b5 are hypothesized to result from a cyt b5-induced conformational change in CYP2C9 that results in an increased collision frequency between the iron-oxygen species (Cpd I) and the substrate, and a decrease in the oxidase activity. Together, these findings suggest that cyt b5 can alter multiple steps in the P450 catalytic cycle via complex interactions with P450 and P450 reductase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17446262      PMCID: PMC2386961          DOI: 10.1124/dmd.107.014910

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  31 in total

1.  Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase.

Authors:  H Yamazaki; T Shimada; M V Martin; F P Guengerich
Journal:  J Biol Chem       Date:  2001-06-18       Impact factor: 5.157

2.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.

Authors:  K Venkatakrishnan; L L von Moltke; M H Court; J S Harmatz; C L Crespi; D J Greenblatt
Journal:  Drug Metab Dispos       Date:  2000-12       Impact factor: 3.922

Review 3.  The use of heterologously expressed drug metabolizing enzymes--state of the art and prospects for the future.

Authors:  C L Crespi; V P Miller
Journal:  Pharmacol Ther       Date:  1999-11       Impact factor: 12.310

4.  Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9.

Authors:  Charles W Locuson; Peter M Gannett; Timothy S Tracy
Journal:  Arch Biochem Biophys       Date:  2006-03-02       Impact factor: 4.013

Review 5.  The roles of cytochrome b5 in cytochrome P450 reactions.

Authors:  Todd D Porter
Journal:  J Biochem Mol Toxicol       Date:  2002       Impact factor: 3.642

6.  Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.

Authors:  Timothy S Tracy; J Matthew Hutzler; Robert L Haining; Allan E Rettie; Matthew A Hummel; Leslie J Dickmann
Journal:  Drug Metab Dispos       Date:  2002-04       Impact factor: 3.922

7.  Interaction of apo-cytochrome b5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions.

Authors:  O L Guryev; A A Gilep; S A Usanov; R W Estabrook
Journal:  Biochemistry       Date:  2001-04-24       Impact factor: 3.162

8.  Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.

Authors:  Hiroshi Yamazaki; Mami Nakamura; Tomoko Komatsu; Katsuhiro Ohyama; Naoya Hatanaka; Satoru Asahi; Noriaki Shimada; F Peter Guengerich; Tsutomu Shimada; Miki Nakajima; Tsuyoshi Yokoi
Journal:  Protein Expr Purif       Date:  2002-04       Impact factor: 1.650

9.  Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities.

Authors:  Miki Nakajima; Kazuhiro Tane; Sumika Nakamura; Noriaki Shimada; Hiroshi Yamazaki; Tsuyoshi Yokoi
Journal:  J Pharm Sci       Date:  2002-04       Impact factor: 3.534

Review 10.  The many roles of cytochrome b5.

Authors:  John B Schenkman; Ingela Jansson
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

View more
  16 in total

1.  CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.

Authors:  Murali Subramanian; Michael Low; Charles W Locuson; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2009-05-15       Impact factor: 3.922

2.  CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus.

Authors:  Murali Subramanian; Harrison Tam; Helen Zheng; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2010-03-09       Impact factor: 3.922

3.  Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

Authors:  Rüdiger Kaspera; Suresh B Naraharisetti; Eric A Evangelista; Kristin D Marciante; Bruce M Psaty; Rheem A Totah
Journal:  Biochem Pharmacol       Date:  2011-06-24       Impact factor: 5.858

4.  Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions.

Authors:  Diane Ramsden; Donald J Tweedie; Tom S Chan; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2014-08-25       Impact factor: 3.922

5.  Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.

Authors:  Anna L Blobaum; Thomas M Bridges; Frank W Byers; Mark L Turlington; Margrith E Mattmann; Ryan D Morrison; Claire Mackie; Hilde Lavreysen; José M Bartolomé; Gregor J Macdonald; Thomas Steckler; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2013-09-03       Impact factor: 3.922

6.  Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism.

Authors:  Chris D Bostick; Katherine M Hickey; Lance A Wollenberg; Darcy R Flora; Timothy S Tracy; Peter M Gannett
Journal:  Drug Metab Dispos       Date:  2016-03-09       Impact factor: 3.922

Review 7.  Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions.

Authors:  Dmitri R Davydov
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-12       Impact factor: 4.481

8.  Cross-linking mass spectrometry and mutagenesis confirm the functional importance of surface interactions between CYP3A4 and holo/apo cytochrome b(5).

Authors:  Chunsheng Zhao; Qiuxia Gao; Arthur G Roberts; Scott A Shaffer; Catalin E Doneanu; Song Xue; David R Goodlett; Sidney D Nelson; William M Atkins
Journal:  Biochemistry       Date:  2012-11-14       Impact factor: 3.162

9.  Variability in Human In Vitro Enzyme Kinetics.

Authors:  Christopher R Gibson; Ying-Hong Wang; Ninad Varkhede; Bennett Ma
Journal:  Methods Mol Biol       Date:  2021

10.  The use of immobilized cytochrome P4502C9 in PMMA-based plug flow bioreactors for the production of drug metabolites.

Authors:  Lance A Wollenberg; Jarod L Kabulski; Matthew J Powell; Jifeng Chen; Darcy R Flora; Timothy S Tracy; Peter M Gannett
Journal:  Appl Biochem Biotechnol       Date:  2013-10-30       Impact factor: 2.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.